The Role of Optic Nerve Sheath Fenestration in Leukemic Patients Having Increased Intracranial Pressure

Optic Nerve Sheath Fenestration Clinical Trial

Official title: The Role of Optic Nerve Sheath Fenestration in Leukemic Patients Having Increased Intracranial Pressure

Status Active, not recruiting

Clinical Trial Summary

Optic nerve sheath fenestration (ONSF) first described by De Wecker in 1872 for the treatment of neuroretinitis. Since then, optic nerve sheath fenestration has become well established procedure for treatment of papilledema in medically uncontrolled patients of idiopathic intracranial hypertension.

Clinical Trial Description

Optic nerve sheath fenestration (ONSF) first described by De Wecker in 1872 for the treatment of neuroretinitis. Since then optic nerve sheath fenestration has become well established procedure for treatment of papilledema in medically uncontrolled patients of idiopathic intracranial hypertension. Indications for ONSF in cancer patients are not well established, but a few case reports have shown success of ONSF in patients with perineural metastasis of breast cancer, increased intracranial pressure with papilledema due to a brain tumor, leukemia and optic nerve sheath meningioma. This study is conducted to establish the role of optic nerve sheath Fenestration in leukemic patients mainly those suffering from acute lymphoblastic leukemia. ;

Related Conditions & MeSH terms

• Intracranial Hypertension
• Leukemic Patients With Increased Intracranial Pressure
• Optic Nerve Sheath Fenestration

• NCT number: NCT04431882
• Study type: Interventional
• Source: Alexandria University
• Status: Active, not recruiting
• Phase: Phase 2/Phase 3
• Start date: June 1, 2019
• Completion date: June 30, 2020